About the Company
Omega-3-acid ethyl esters are a mixture of ethyl eicosapentaenoic acid and ethyl docosahexaenoic acid, which are ethyl esters of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil. Together with dietary changes, they are used to treat high blood triglycerides which may reduce the risk of pancreatitis. They are generally less preferred than statins, and use is not recommended by NHS Scotland as the evidence does not support a decreased risk of heart disease. Omega-3-acid ethyl esters are taken by mouth. Common side effects include burping, nausea, and an upset abdomen. Serious side effects may include liver problems and anaphylaxis. While use in pregnancy has not been well studied, some omega-3 fatty acids appear beneficial. How it works is not entirely clear. Experts found a dose-dependent increase in the risk for atrial fibrillation in patients with cardiovascular diseases or cardiovascular risk factors who were being treated with omega-3-acid ethyl esters compared with those treated with placebo. The observed risk was at its highest at a dose of 4 g/d.[1] Omega-3-acid ethyl ester medicines were approved for medical use in the European Union in 2000 and in the United States in 2004. Beyond the branded prescription formulation, it is also available as a generic medication and over the counter. In 2021, it was the 218th most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $OMGA News
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Wall Street expects a year-over-year increase in earnings on higher revenues when Omega Therapeutics, Inc. (OMGA) reports results for the quarter ended March 2024. While this widely-known consensus ...
Omega Therapeutics Inc (OMGA): A Technical Analysis
Based on Omega Therapeutics Inc (OMGA), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -3.03. The debt to equity ratio ...
Omega Therapeutics CFO Joshua Reed to depart
Omega Therapeutics (NASDAQ:OMGA) and Chief Financial Officer Joshua Reed have agreed to terminate his employment effective as of May 31, the company said. On April 16, the Board of Directors of the ...
Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Omega Therapeutics (OMGA), indicating that the stock has found support. This, combined with an upward trend in earnings ...
11 Oversold MidCap Stocks To Buy Now
In this piece, we will take a look at the 11 oversold midcap stocks to buy now. If you want to skip our coverage of ...
Beyond the Pill Market Growth and Restrain Factors Analysis Report
The Global Beyond The Pill Market Size is predicted to register at an 11.62% CAGR during the forecast period for 2024-2031. Request for Free Sample Pages: ...
NDAQ Stock Earnings: Nasdaq Misses EPS, Beats Revenue for Q1 2024
Stock Market News, Stock Advice & Trading Tips Nasdaq (NASDAQ:NDAQ) just reported results for the first quarter of ...
Why Is Laser Photonics (LASE) Stock Up 130% Today?
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Laser Photonics (NASDAQ:LASE) stock is rocketing higher on Tuesday after the ...
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
The post The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024 appeared first on InvestorPlace.
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Gilead Sciences Inc. GILD is set to report first-quarter 2024 results on Apr 25, after market close. In the last reported ...
INTERVIEW: Omega Psi Phi Fraternity, Inc. on upcoming events in the Chattahoochee Valley area
Keep Columbus Beautiful to wrap up Earth Week with community awareness events ...
Allergy Diagnostics and Therapeutics Market Surges to USD 79.6 Billion by 2033
According to Market.us, the anticipated value of the Global Allergy Diagnostics and Therapeutics Market is projected to reach ...
Loading the latest forecasts...